715 related articles for article (PubMed ID: 19891248)
1. [Upstream therapy of atrial fibrillation in patients with heart failure].
Alboni P; Gianfranchi L; Pacchioni F
G Ital Cardiol (Rome); 2009 Sep; 10(9):566-71. PubMed ID: 19891248
[TBL] [Abstract][Full Text] [Related]
2. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.
Savelieva I; Kakouros N; Kourliouros A; Camm AJ
Europace; 2011 Mar; 13(3):308-28. PubMed ID: 21345926
[TBL] [Abstract][Full Text] [Related]
3. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation.
Richter B; Derntl M; Marx M; Lercher P; Gössinger HD
Am Heart J; 2007 Jan; 153(1):113-9. PubMed ID: 17174648
[TBL] [Abstract][Full Text] [Related]
4. [Unsatisfactory results of upstream therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for the prevention of recurrent atrial fibrillation].
Disertori M; Zeni P; Quintarelli S; Bonmassari R
G Ital Cardiol (Rome); 2010 Nov; 11(11):829-34. PubMed ID: 21348320
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation.
Anand K; Mooss AN; Hee TT; Mohiuddin SM
Am Heart J; 2006 Aug; 152(2):217-22. PubMed ID: 16875900
[TBL] [Abstract][Full Text] [Related]
6. Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation--indications and contraindications.
Lévy S
Nat Clin Pract Cardiovasc Med; 2006 Apr; 3(4):220-5. PubMed ID: 16568131
[TBL] [Abstract][Full Text] [Related]
7. The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation.
Al Chekakie MO; Akar JG; Wang F; Al Muradi H; Wu J; Santucci P; Varma N; Wilber DJ
J Cardiovasc Electrophysiol; 2007 Sep; 18(9):942-6. PubMed ID: 17593228
[TBL] [Abstract][Full Text] [Related]
8. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation.
Savelieva I; Camm J
Nat Clin Pract Cardiovasc Med; 2008 Jan; 5(1):30-41. PubMed ID: 18094671
[TBL] [Abstract][Full Text] [Related]
9. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
Makkar KM; Sanoski CA; Spinler SA
Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
[TBL] [Abstract][Full Text] [Related]
10. [Non-antiarrhythmic drug therapy for the prevention of atrial fibrillation?].
Fauchier L; Zannad N; Clementy N; Pierre B; Cosnay P; Babuty D
Ann Cardiol Angeiol (Paris); 2010 Dec; 59 Suppl 1():S28-32. PubMed ID: 21211623
[TBL] [Abstract][Full Text] [Related]
11. Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation.
Nieuwlaat R; Eurlings LW; Cleland JG; Cobbe SM; Vardas PE; Capucci A; López-Sendòn JL; Meeder JG; Pinto YM; Crijns HJ
J Am Coll Cardiol; 2009 May; 53(18):1690-8. PubMed ID: 19406345
[TBL] [Abstract][Full Text] [Related]
12. Clinical trials, the renin angiotensin system and atrial fibrillation.
Birnie DH; Gollob M; Healey JS
Curr Opin Cardiol; 2006 Jul; 21(4):368-75. PubMed ID: 16755207
[TBL] [Abstract][Full Text] [Related]
13. Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling.
Healey JS; Morillo CA; Connolly SJ
Curr Opin Cardiol; 2005 Jan; 20(1):31-7. PubMed ID: 15596957
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.
Disertori M; Latini R; Maggioni AP; Delise P; Di Pasquale G; Franzosi MG; Staszewsky L; Tognoni G;
J Cardiovasc Med (Hagerstown); 2006 Jan; 7(1):29-38. PubMed ID: 16645357
[TBL] [Abstract][Full Text] [Related]
15. Upstream therapy of atrial fibrillation.
Smit MD; Van Gelder IC
Expert Rev Cardiovasc Ther; 2009 Jul; 7(7):763-78. PubMed ID: 19589113
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation.
Lip GY; Frison L; Grind M
J Intern Med; 2007 Jun; 261(6):577-86. PubMed ID: 17547713
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the renin-angiotensin system for prevention of atrial fibrillation.
Zografos T; Katritsis DG
Pacing Clin Electrophysiol; 2010 Oct; 33(10):1270-85. PubMed ID: 20636314
[TBL] [Abstract][Full Text] [Related]
18. The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials.
Zhang Y; Zhang P; Mu Y; Gao M; Wang JR; Wang Y; Su LQ; Hou YL
Clin Pharmacol Ther; 2010 Oct; 88(4):521-31. PubMed ID: 20811347
[TBL] [Abstract][Full Text] [Related]
19. Inefficiency of renin-angiotensin inhibitors in preventing atrial fibrillation in patients with a normal heart.
Fazio G; Pizzuto C; Sutera L; Guttilla D; Di Gesaro G; Cascio C; Novo G; Assennato P; Novo S
Minerva Cardioangiol; 2007 Jun; 55(3):311-5. PubMed ID: 17534249
[TBL] [Abstract][Full Text] [Related]
20. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study.
Salehian O; Healey J; Stambler B; Alnemer K; Almerri K; Grover J; Bata I; Mann J; Matthew J; Pogue J; Yusuf S; Dagenais G; Lonn E;
Am Heart J; 2007 Sep; 154(3):448-53. PubMed ID: 17719288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
